NCT00401076已完成3 期
A One-year Open-label Study to Assess the Safety of Oral Long-term Use of SA-001 in Patients With Pancreatic Exocrine Insufficiency Caused by Chronic Pancreatitis or by Pancreatectomy
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Abbott
- 入组人数
- 80
- 试验地点
- 17
- 主要终点
- Safety of long-term use of 3.0 g/day SA 001 (12 capsules/day), flexibly increased or decreased within the range of 1.5 g/day SA 001 (6 capsules/day) to 6.0 g/day SA-001 (24 capsules/day)
研究概览
简要总结
This study is to evaluate the safety of 3.0 g/day of SA-001 (to be flexibly increased or decreased with the range from 1.5 g/day to 6.0 g/day), which will orally be administered for 52 weeks to patients with pancreatic exocrine insufficiency caused by chronic pancreatitis in the non-compensatory stage or by pancreatectomy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
1
Experimental
干预措施: SA-001 (Drug)
结局指标
主要结局
Safety of long-term use of 3.0 g/day SA 001 (12 capsules/day), flexibly increased or decreased within the range of 1.5 g/day SA 001 (6 capsules/day) to 6.0 g/day SA-001 (24 capsules/day)
时间窗: 52 weeks
次要结局
- Efficacy data (nutritional evaluation items) of 3.0 g/day SA-001 (12 capsules/day), flexibly increased or decreased within the range of 1.5 g/day SA 001 (6 capsules/day) to 6.0 g/day SA-001 (24 capsules/day)(52 weeks)
研究者
研究点 (17)
Loading locations...
相似试验
招募中
1 期
Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid TumorsAdvanced Solid TumorNCT06072989Shanghai East Hospital24
已完成
1 期
Study of a Latanoprost Ocular Implant for Treatment of Open Angle Glaucoma or Ocular Hypertension.Open Angle GlaucomaOcular HypertensionNCT05333419PolyActiva Pty Ltd1
招募中
1 期
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668Advanced Solid TumorNCT05341570Betta Pharmaceuticals Co., Ltd.60
招募中
1 期
A Study of BPI-460372 in Advanced Solid Tumor PatientsAdvanced Solid TumorNCT05789602Betta Pharmaceuticals Co., Ltd.82
终止
1 期
Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical ProceduresHead and Neck CancerNCT01987375Eben Rosenthal1